Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells

Molecular Pharmacology

Volumn 79, Issue 5, 2011, Pages 833-843

  Albiñana, Virginia ^a   Sanz Rodríguez, Francisco ^b   Recio Poveda, Lucía ^a   Bernabéu, Carmelo ^a   Botella, Luisa M ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ENDOGLIN; MESSENGER RNA; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA;

ANEMIA; ARTERIOVENOUS MALFORMATION; ARTICLE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; EPISTAXIS; HUMAN; HUMAN CELL; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENDU OSLER WEBER DISEASE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 79954990980     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.067447     Document Type: Article

References (35)

1. Abdalla SA and Letarte M (2006) Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 43:97-110. (Pubitemid 43262964)
2. Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, Bernabéu C, and Botella LM (2010) Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cellss. Thromb Haemost 103:525-534.
3. Bayrak-Toydemir P, McDonald J, Akarsu N, Toydemir RM, Calderon F, Tuncali T, Tang W, Miller F, and Mao R (2006) A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet 140:2155-2162. (Pubitemid 44522429)
4. Bernabeu C, Langa C, Garrido-Martin EM, and Botella LM (2010) Involvement of the TGF-beta superfamily signalling pathway in hereditary haemorragic telangi-ectasia. J Appl Biomed 8:169-177.
5. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, and Bernabeu C (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 204:574-584. (Pubitemid 40934653)
6. Botella LM, Sánchez-Elsner T, Rius C, Corbí A, and Bernabéu C (2001) Identification of a critical Sp1 site within the endoglin promoter and its involvement in the transforming growth factor-beta stimulation. J Biol Chem 276:34486-34494.
7. Cole SG, Begbie ME, Wallace GM, and Shovlin CL (2005) A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 42:577-582. (Pubitemid 40993833)
8. Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F, Ramirez JR, Morales-Angulo C, Zarrabeitia R, Perez-Molino A, Bernabéu C, and Botella LM (2007) Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Hae-most 97:254-262. (Pubitemid 46592146)
9. Fernandez-L A, Sanz-Rodriguez F, Zarrabeitia R, Pérez-Molino A, Hebbel RP, Nguyen J, Bernabéu C, and Botella LM (2005) Blood outgrowth endothelial cells from Hereditary Haemorrhagic Telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res 68:235-248. (Pubitemid 41428420)
10. Fernandez LA, Sanz-Rodriguez F, Zarrabeitia R, Perez-Molino A, Morales C, Re-strepo CM, Ramirez JR, Coto E, Lenato GM, Bernabeu C, et al. (2006) Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia and expression analysis of Endoglin and ALK1. Hum Mutat 27:295.
11. Fontalba A, Fernandez-L A, García-Alegria E, Albiñana V, Garrido-Martin EM, Blanco FJ, Zarrabeitia R, Perez-Molino A, Bernabeu-Herrero ME, Ojeda ML, et al. (2008) Mutation study of Spanish patients with hereditary hemorrhagic telangi-ectasia. BMC Med Genet 9:75.
12. Garrido-Martin EM, Blanco FJ, Fernandez-L A, Langa C, Vary CP, Lee UE, Friedman SL, Botella LM, and Bernabeu C (2010) Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Mol Biol 11:51.
13. Ghosh K and Ghosh K (2008) Hereditary haemorrhagic telangiectasia (HHT): negotiating between the Scylla of bleeding and Charybdis of thrombosis. Thromb Haemost 100:162-164. (Pubitemid 351948763)
14. Giordano A, Romano S, Mallardo M, D'Angelillo A, Calì G, Corcione N, Ferraro P, and Romano MF (2008) FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res 79:519-526.
15. Jessurun GA, Kamphuis DJ, van der Zande FH, and Nossent JC (1993) Cerebral arteriovenous malformations in The Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arte-riovenous malformations. Clin Neurol Neurosurg 95:193-198. (Pubitemid 23288235)
16. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, Stenzel TT, Speer M, Pericak-Vance MA, Diamond A, et al. (1996) Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13:189-195.
17. Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, Kohsaka M, Aoki H, and Imanaka H (1987a) FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot 40:1249-1255. (Pubitemid 17138109)
18. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, Goto T, Okuhara M, Kohsaka M, and Aoki H (1987b) FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot 40:1256-1265. (Pubitemid 17138110)
19. Kjeldsen AD, Vase P, and Green A (1999) Hereditary haemorrhagic telangiectasia: a population-based study of prevalence and mortality in Danish patients. J Intern Med 245:31-39. (Pubitemid 29049140)
20. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, Mummery C, Arthur HM, and ten Dijke P (2004) Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 23:4018-4028. (Pubitemid 39472423)
21. Marchuk DA, Gallione CJ, Morrison LA, Clericuzio CL, Hart BL, Kosofsky BE, Louis DN, Gusella JF, Davis LE, and Prenger VL (1995) A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics 28:311-314.
22. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, Helmbold EA, Markel DS, McKinnon WC, and Murrell J (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemor-rhagic telangiectasia type 1. Nat Genet 8:345-351.
23. McConnell JL and Wadzinski BE (2009) Targeting protein serine/threonine phos-phatases for drug development. Mol Pharmacol 75:1249-1261.
24. Morales-Angulo C, Pérez del Molino A, Zarrabeitia R, Fernández A, Sanz-Rodríguez F, and Botella LM (2007) [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. Acta Otorrino-laringol Esp 58:129-132. (Pubitemid 47251038)
25. Morales-Angulo C and del Valle-Zapico A (1998) A Hereditary hemorrhagic telangi-ectasia. Otolaryngol Head Neck Surg 119:293.
26. Plauchu H, de Chadarévian JP, Bideau A, and Robert JM (1989) Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 32:291-297. (Pubitemid 19146524)
27. Rajnoch J, Lodererova A, Szabo A, Honsova E, Vannay A, Bloudickova S, Matl I, and Viklicky O (2005) Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: effect of tacrolimus. Transplant Proc 37:352-354. (Pubitemid 40459783)
28. Ríus C, Smith JD, Almendro N, Langa C, Botella LM, Marchuk DA, Vary CP, and Bernabéu C (1998) Cloning of the promoter region of human endoglin, the target gene for hereditary hemorrhagic telangiectasia type 1. Blood 92:4677-4690. (Pubitemid 29005870)
29. Sánchez-Elsner T, Botella LM, Velasco B, Langa C, and Bernabéu C (2002) Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 277:43799-43808. (Pubitemid 36157800)
30. Shovlin CL (2010) Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 24:203-219.
31. Shovlin CL and Letarte M (1999) Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 54:714-729. (Pubitemid 29341410)
32. Shovlin CL, Sulaiman NL, Govani FS, Jackson JE, and Begbie ME (2007) Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): association with venous thromboembolism. Thromb Haemost 98:1031-1039. (Pubitemid 350091132)
33. Skaro AI, Marotta PJ, and McAlister VC (2006) Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann Intern Med 144:226-227. (Pubitemid 46780712)
34. Udina e and Navarro X (2002) [Immunophilins: neuroprotective agents and promoters of neural regeneration]. Neurologia 17:200-213. (Pubitemid 35252370)
35. Zacharski LR, Dunbar SD, and Newsom WA Jr (2001) Hemostatic effects of tamox-ifen in hereditary hemorrhagic telangiectasia. Thromb Haemost 85:371-372. (Pubitemid 32140589)